Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2021
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Ampersand Biomedicines founded?
Ampersand Biomedicines was founded in 2021.
What industry is Ampersand Biomedicines in?
Ampersand Biomedicines operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Find investors for your startup like Ampersand Biomedicines
Gritt sends AI-personalised outreach to each investor — from your Gmail
